Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey

DOI: https://doi.org/10.1177/24755303231195870

Abstract:[This corrects the article DOI: 10.1177/2475530320956602.].

What problem does this paper attempt to address?

Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

DOI: https://doi.org/10.1177/24755303231195869

Abstract:[This corrects the article DOI: 10.1177/2475530320950265.].
Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey

DOI: https://doi.org/10.1177/24755303231195873

Abstract:[This corrects the article DOI: 10.1177/24755303211067822.].
Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

DOI: https://doi.org/10.1177/24755303231195867

Abstract:[This corrects the article DOI: 10.1177/24755303221131257.].
Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

DOI: https://doi.org/10.1177/24755303231195871

Abstract:[This corrects the article DOI: 10.1177/2475530320910466.].
Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

DOI: https://doi.org/10.1177/26335565231223601

2023-12-01

Journal of Multimorbidity and Comorbidity

Abstract:[This corrects the article DOI: 10.1177/26335565231212336.].
Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

DOI: https://doi.org/10.1177/24755303231195874

Abstract:[This corrects the article DOI: 10.1177/24755303211056059.].
Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options

DOI: https://doi.org/10.1177/24755303231195875

Abstract:[This corrects the article DOI: 10.1177/24755303221099292.].
Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

DOI: https://doi.org/10.1177/24755303231195864

Abstract:[This corrects the article DOI: 10.1177/2475530320925067.].
Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

DOI: https://doi.org/10.1177/24755303231195884

Abstract:[This corrects the article DOI: 10.1177/24755303211029598.].
Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

DOI: https://doi.org/10.1177/24755303231195863

Abstract:[This corrects the article DOI: 10.1177/2475530320970530.].
Erratum: Psoriasis comorbidity management in the COVID era: a pressing challenge

Frontiers Production Office

DOI: https://doi.org/10.3389/fmicb.2024.1502059

IF: 5.2

2024-10-08

Frontiers in Microbiology

Abstract:This article is an erratum on: Psoriasis comorbidity management in the COVID era: a pressing challenge

microbiology
Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

DOI: https://doi.org/10.1177/24755303231195882

Abstract:[This corrects the article DOI: 10.1177/24755303221077211.].
Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring

DOI: https://doi.org/10.1177/24755303231195872

Abstract:[This corrects the article DOI: 10.1177/24755303211011477.].
Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

DOI: https://doi.org/10.1177/24755303231195857

Abstract:[This corrects the article DOI: 10.1177/2475530321995516.].
Corrigendum to Prevalence of syphilis among people living with HIV who attend a large urban antiretroviral therapy clinic in Panama: a cross-sectional epidemiological study

DOI: https://doi.org/10.1177/20499361241263641

2024-06-20

Abstract:[This corrects the article DOI: 10.1177/20499361241256290.].
Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

DOI: https://doi.org/10.1177/24755303231195868

Abstract:[This corrects the article DOI: 10.1177/24755303211051724.].
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg,Joseph F. Merola,Knut Schäkel,Luis Puig,Patrick D. Mahar,Isabella Yali Wang,Imre Pavo,Christopher Schuster,Christopher E. M. Griffiths

DOI: https://doi.org/10.3389/fmed.2023.1171132

IF: 3.9

2023-03-10

Frontiers in Medicine

Abstract:[This corrects the article DOI: 10.3389/fmed.2022.1092688.].

medicine, general & internal
Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

DOI: https://doi.org/10.1177/24755303231195862

Abstract:[This corrects the article DOI: 10.1177/2475530320970538.].
Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report

DOI: https://doi.org/10.1177/24755303231196711

Abstract:[This corrects the article DOI: 10.1177/2475530320950290.].
Corrigendum to "Pranic Healing as a Complementary Therapy in Diabetic Foot Ulcer Management: A Randomised, Controlled, Double-Blind Trial"

DOI: https://doi.org/10.1177/27536130241228055

2024-09-12

Abstract:[This corrects the article DOI: 10.1177/27536130231183429.].

Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey

Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey

Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options

Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

Erratum: Psoriasis comorbidity management in the COVID era: a pressing challenge

Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring

Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

Corrigendum to Prevalence of syphilis among people living with HIV who attend a large urban antiretroviral therapy clinic in Panama: a cross-sectional epidemiological study

Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report

Corrigendum to "Pranic Healing as a Complementary Therapy in Diabetic Foot Ulcer Management: A Randomised, Controlled, Double-Blind Trial"